Peiran Liu
About Peiran Liu
Peiran Liu is the Director and Global Product Quality Lead for commercial cell therapy products at Bristol Myers Squibb, with extensive experience in analytical chemistry and regulatory filings.
Director at Bristol Myers Squibb
Peiran Liu is currently serving as Director, Global Product Quality Lead for commercial cell therapy products at Bristol Myers Squibb. In this role, Liu oversees the quality and regulatory compliance of cell therapy products, ensuring they meet rigorous standards. This position highlights his expertise in the field of commercial cell therapy and product quality management.
Previous Roles at Bristol Myers Squibb
Before his current role, Peiran Liu has held several important positions within Bristol Myers Squibb. From 2020 to 2023, he served as Associate Director Biologics CMC Quality Assurance and Quality Product Lead. Prior to that, he worked as a Senior Principle Scientist and Senior Research Investigator between 2016 and 2020. From 2010 to 2015, he was the Biologics Analytical Team Lead (CMC manager) based in Hopewell, New Jersey. Peiran Liu also held the role of Research Investigator from 2004 to 2009.
Educational Background in Analytical Chemistry
Peiran Liu obtained his Doctor of Philosophy (PhD) in Analytical Chemistry from Purdue University. His academic training provided him with a strong foundation in developing analytical methodologies, which he has effectively applied throughout his career in the biopharmaceutical industry.
Expertise in Analytical Strategies and Protein Characterization
Peiran Liu has extensive experience in developing analytical strategies for in-process development as well as drug substance and drug product biochemical and biophysical analysis. He is accountable for activities such as protein characterization, process comparability determinations, and critical quality attributes analysis. His work ensures that therapeutic products are safe, effective, and of high quality.
Experience with Regulatory Filings and Early Phase Product Quality
Peiran Liu has substantial experience in regulatory filings, including the authoring of Investigational New Drug (IND) and Biologics License Applications (BLA), as well as responding to Health Authority inquiries. He has also served as the early phase product quality lead for biologics and gene therapy products, contributing to the development and regulatory approval of innovative therapies.